Skip to main content

Table 4 Summary of current clinical trials targeting DNA methylation in melanoma

From: Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities

Approach

Phase

Status

Clinical trial identifier

Guadecitabine + ipilimumab for unresectable disease

I

Recruiting

NCT02608437

Oral azacitidine + pembrolizumab for metastatic melanoma

II

Recruiting soon

NCT02816021

Azacitidine + rInterferon alfa2b for stage III/IV unresectable

I/II

Completed, results not reported

NCT00217542

Oral azacitidine bioequivalence study

I

Recruiting

NCT02223052

Decitabine + vemurafenib + cobimetinib for resistant disease

I/II

Recruiting

NCT01876641